Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Sunshine Biopharma (SBFM) Cost of Revenue (2018 - 2026)

Sunshine Biopharma filings provide 8 years of Cost of Revenue readings, the most recent being $5.5 million for Q4 2025.

  • On a quarterly basis, Cost of Revenue rose 133.1% to $5.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $24.1 million, a 323.95% increase, with the full-year FY2025 number at $24.1 million, up 2457.78% from a year prior.
  • Cost of Revenue hit $5.5 million in Q4 2025 for Sunshine Biopharma, down from $6.3 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $15.3 million in Q4 2023 to a low of -$16.8 million in Q4 2024.
  • Median Cost of Revenue over the past 5 years was $207856.0 (2022), compared with a mean of $1.8 million.
  • Biggest five-year swings in Cost of Revenue: plummeted 640.39% in 2021 and later surged 8482.28% in 2023.
  • Sunshine Biopharma's Cost of Revenue stood at -$56541.0 in 2021, then skyrocketed by 414.28% to $177699.0 in 2022, then surged by 8482.28% to $15.3 million in 2023, then plummeted by 209.91% to -$16.8 million in 2024, then soared by 133.1% to $5.5 million in 2025.
  • The last three reported values for Cost of Revenue were $5.5 million (Q4 2025), $6.3 million (Q3 2025), and $6.0 million (Q2 2025) per Business Quant data.